GEN Exclusives

More »

GEN News Highlights

Back to Item »

BMS Hands Co-Development Rights for Anticancer Drug Back to Exelixis along with $17M

Firm hopes to file NDA in 2011 for XL184 as a treatment for medullary thyroid cancer.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Tackling Climate Change

Do you think most companies will respond positively to the People’s Climate March?